
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen has demonstrated impressive sales growth, with a 40% increase in the third quarter of 2025 compared to the same period in 2024, driven by multiple products showing double-digit growth, including significant performance from Repatha and Tezspire. The company has raised its fiscal year 2025 revenue guidance to a range of $35.8 billion to $36.6 billion, reflecting continued strength across its established therapeutic franchises and a robust pipeline bolstered by recent acquisitions. Additionally, Amgen is prioritizing research and development with a planned growth rate of over 20% in 2025, indicating a commitment to innovation and future revenue generation in the biotechnology sector.
Bears say
Amgen's financial outlook is negatively impacted by projected revenue growth of only approximately 1% in 2026, which is exacerbated by expected annual sales declines of around 28% for Prolia and 39% for Xgeva. Additionally, management indicated that growth in research and development spending will be more restrained relative to 2025, which could limit future innovation and competitiveness. Overall, despite Amgen's strong existing product portfolio and cash flows, the impending loss of exclusivity for key drugs and uncertain prospects for emerging products raise concerns about sustainable long-term growth.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares